SESSION TITLE: Thoracic Surgery Posters
SESSION TYPE: Poster Presentations
PRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PM
PURPOSE: Video-assisted thoracic surgery (VATS) sympathectomy is the definitive therapy for primary palmar hyperhidrosis with high success rates and low recurrence. Classically, a 3-port bilateral VATS approach is utilized. We report our novel application and experience of single-port VATS sympathectomy with the VasoView® endoscopic vein harvesting devices.
METHODS: Fourteen patients underwent single port VasoView® sympathectomy between June 2011 and February 2013. The patients received general anaesthesia and double lumen endobronchial tube intubation. A single incison for surgical access was made bilaterally at the axillary region. Operative details and outcomes are analyzed.
RESULTS: Ten sympathectomy patients (71%) were females, with mean age of 24.7 years (range 17- 36). Bilateral thoracic sympathetic nerve from top R3 to R4 was thermally ablated. Maquet VasoView® Hemopro 1 device was utilized in 8 cases, Hemopro 2 in 3 cases, and 7XS in 3 cases. The mean operative time to complete bilateral procedure was 64 minutes (range 55-82 minutes). The procedure was successful in all patients, with no residual hyperhidrosis. Mean postoperative hospital stay was 1.2 days (range 0.7-1.9 days). Mean visual analogue pain score at discharge was 1.8 (range 1.2-3.4). There was no postoperative complication or mortality. Compensatory hyperhidrosis (truncal predominance) was seen in 2 (14.3%) patient, and there was no recurrence during follow-up. The mean follow-up is 13 months (range 5-24 months).
CONCLUSIONS: Single port VasoView® sympathectomy for primary palmar hyperhidrosis is a safe and effective procedure. The long term outcomes and potential benefits of a single port technique warrant further investigation
CLINICAL IMPLICATIONS: The development of novel minimal invasive surgical instruments and surgeons' innovation further minimize surgical trauma.
DISCLOSURE: The following authors have nothing to disclose: Rainbow Lau, Calvin Ng, Randolph Wong, Eugene Yeung, Micky Kwok, Innes Wan, Malcolm Underwood
No Product/Research Disclosure Information